SARATON SHAROITIDA QON TOMIR REAKTIVLIGI: ENDOTELIAL VA ION-TRANSPORT MEXANIZMLARI, EKSPERIMENTAL BAHOLASH VA KORREKSIYA ISTIQBOLLARI
Keywords:
saraton, vaskulyar reaktivlik, endoteliy, NO, CaV1.2, SERCA, NCX, oksidlovchi stress, aorta halqalariAbstract
Saratonning qon tomir tizimiga ta’siri o‘sma ichidagi angiogenez bilan cheklanmaydi: yallig‘lanish, oksidlovchi stress va immunotrombotik jarayonlar periferik tomir funksiyasini ham o‘zgartirishi mumkin. Ushbu sharhda patologik o‘sma tomirlari, davolanmagan saratonga bog‘liq tizimli o‘zgarishlar va onkologik muolajalarning vaskulyar nojo‘ya ta’sirlari alohida tahlil qilindi. Diqqat eNOS–NO/endotelin-1 muvozanati, silliq mushakning CaV1.2 va α₁-adrenoretseptor yo‘llari, SERCA, NCX, Na⁺/K⁺-ATFaza hamda K⁺ kanallariga qaratildi. Nashr etilgan dalillar endotelial buzilish va o‘sma ta’sirida periferik perfuziya pasayishini qo‘llab-quvvatlasa-da, katta arteriyalarda ion-transport tizimlarining bevosita o‘zgarishini isbotlovchi ma’lumotlar chegaralangan. Shu bois aorta halqalarida KCl, fenilefrin, ACh/SNP va tanlangan blokatorlar bilan bajariladigan ex vivo tajribalar istiqbolli mexanistik yondashuv sifatida muhokama qilinadi. Biologik faol moddalarning in vivo qo‘llanishidan keyingi funksional tekshiruvlarini o‘sma yuklamasi va molekulyar ko‘rsatkichlar bilan birlashtirish tavsiya etiladi.
References
International Agency for Research on Cancer (IARC). Global cancer burden growing, amidst mounting need for services. GLOBOCAN 2022 estimates. Lyon: IARC/WHO; 2024.
Cedervall J, Dimberg A, Olsson AK. Tumor-Induced Local and Systemic Impact on Blood Vessel Function. Mediators Inflamm. 2015;2015:418290. doi:10.1155/2015/418290.
Cedervall J, Zhang Y, Huang H, et al. Neutrophil Extracellular Traps Accumulate in Peripheral Blood Vessels and Compromise Organ Function in Tumor-Bearing Animals. Cancer Res. 2015;75(13):2653-2662. doi:10.1158/0008-5472.CAN-14-3299.
Cedervall J, Dimberg A, Olsson AK. Tumor-induced neutrophil extracellular traps—drivers of systemic inflammation and vascular dysfunction. Oncoimmunology. 2016;5(3):e1098803. doi:10.1080/2162402X.2015.1098803.
Preuss SF, Grieshober D, Augustin HG. Systemic Reprogramming of Endothelial Cell Signaling in Metastasis and Cachexia. Physiology (Bethesda). 2023;38(4):189-202. doi:10.1152/physiol.00001.2023.
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62. doi:10.1126/science.1104819.
Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417-427. doi:10.1038/nrd3455.
Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74(2-3):72-84. doi:10.1016/j.mvr.2007.05.003.
Yao X, Zeng Y. Tumour associated endothelial cells: origin, characteristics and role in metastasis and anti-angiogenic resistance. Front Physiol. 2023;14:1199225. doi:10.3389/fphys.2023.1199225.
Leone P, Malerba E, Susca N, et al. Endothelial cells in tumor microenvironment: insights and perspectives. Front Immunol. 2024;15:1367875. doi:10.3389/fimmu.2024.1367875.
Tomita T, Kato M, Hiratsuka S. Regulation of vascular permeability in cancer metastasis. Cancer Sci. 2021;112(8):2966-2974. doi:10.1111/cas.14942.
Tozer GM, Prise VE, Bell KM, Dennis MF, Stratford MR, Chaplin DJ. Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification. Br J Cancer. 1996;74(12):1955-1960. doi:10.1038/bjc.1996.659.
Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376. doi:10.1038/288373a0.
Ghosh D, Syed AU, Prada MP, et al. Calcium Channels in Vascular Smooth Muscle. Adv Pharmacol. 2017;78:49-87. doi:10.1016/bs.apha.2016.08.002.
Trebak M, Ginnan R, Singer HA, Jourd’heuil D. Interplay between calcium and reactive oxygen/nitrogen species: an essential paradigm for vascular smooth muscle signaling. Antioxid Redox Signal. 2010;12(5):657-674. doi:10.1089/ars.2009.2842.
Johny JP, Plank MJ, David T. Importance of Altered Levels of SERCA, IP3R, and RyR in Vascular Smooth Muscle Cell. Biophys J. 2017;112(2):265-287. doi:10.1016/j.bpj.2016.11.3206.
Moccia F, Berra-Romani R, Tanzi F. Update on vascular endothelial Ca2+ signalling: A tale of ion channels, pumps and transporters. World J Biol Chem. 2012;3(7):127-158. doi:10.4331/wjbc.v3.i7.127.
Blaustein MP, Lederer WJ. Sodium/calcium exchange: its physiological implications. Physiol Rev. 1999;79(3):763-854. doi:10.1152/physrev.1999.79.3.763.
Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology. Eur Heart J. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244.
Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17(8):503-522. doi:10.1038/s41569-020-0347-2.
Donisan T, Balanescu DV, Abe JI, Lerman A, Iliescu CA, Herrmann J. Vascular Toxicities of Cancer Therapies: 2025 Update. Arterioscler Thromb Vasc Biol. 2026;46(2):e319867. doi:10.1161/ATVBAHA.125.319867.
Terwoord JD, Beyer AM, Gutterman DD. Endothelial dysfunction as a complication of anti-cancer therapy. Pharmacol Ther. 2022;237:108116. doi:10.1016/j.pharmthera.2022.108116.
Anastasiou M, Oikonomou E, Theofilis P, et al. Prolonged impact of anti-cancer therapy on endothelial function and arterial stiffness in breast cancer patients. Vascul Pharmacol. 2023;152:107195. doi:10.1016/j.vph.2023.107195.
Chitkara A, Kaur N, Desai A, et al. Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: a systematic review and meta-analysis. Cancer Med. 2023;12(24):21579-21591. doi:10.1002/cam4.6662.
Koolen SLW, Danser AHJ. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension. Cardiovasc Res. 2019;115(5):904-914. doi:10.1093/cvr/cvz022.
León-Mateos L, Mosquera J, Antón Aparicio L. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. Redox Biol. 2015;6:421-425. doi:10.1016/j.redox.2015.09.007.
Cohen JB, Brown NJ, Brown SA, et al. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2023;80(3):e46-e57. doi:10.1161/HYP.0000000000000224.
Perna A, Sellitto C, Komici K, et al. Transient Receptor Potential (TRP) Channels in Tumor Vascularization. Int J Mol Sci. 2022;23(22):14253. doi:10.3390/ijms232214253.
Karaki H, Ozaki H, Hori M, et al. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev. 1997;49(2):157-230.
Klein D. The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy. Front Oncol. 2018;8:367. doi:10.3389/fonc.2018.00367.
Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071-1121. doi:10.1152/physrev.00038.2010.
Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs. 2011;25(3):159-169. doi:10.2165/11590180-000000000-00000.





